<DOC>
	<DOCNO>NCT02770482</DOCNO>
	<brief_summary>The combined measurement Ab42 tau protein ( total phosphorylated ) spinal fluid show promising diagnosis Alzheimer 's disease ( AD ) , justified inclusion new diagnostic criterion . However , sometimes yield discordant result discriminant ( isolated variation Ab42 P-181 Tau ) . To answer challenge , new marker develop recent year , namely amyloid beta-peptide 1-40 ( Aβ40 ) . This marker reflect patient 's total amyloid deposit use calculate Aβ42/Aβ40 ratio . This ratio measure relative variation Aβ42 compare total amyloid burden . Literature data topic sparse date , report publish evaluate utility marker diagnostic strategy AD .</brief_summary>
	<brief_title>Amyloid Beta-peptide 1-40 Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Patients attend Memory Clinic ChampagneArdennes memory disorder , Whose diagnostic workup require assessment biomarkers present cerebrospinal fluid consider eligible inclusion study . Patients social security coverage include .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>dementia</keyword>
	<keyword>biomarkers</keyword>
	<keyword>cerebrospinal fluid</keyword>
</DOC>